{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:15:37Z","timestamp":1793171737977,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurodegenerative diseases (NDs) are conditions characterized by irreversible progressive degeneration to the nervous tissue and are usually associated with cognitive decline and functional deficits, especially in elderly. Acetylcholinesterase inhibitors (AChEIs) like donepezil, rivastigmine, and galantamine are commonly prescribed to alleviate cognitive symptoms associated with NDs. However, their long-term impact on slowing structural brain degeneration, particularly hippocampal atrophy, remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis assess the efficacy of AChEIs in reducing hippocampal atrophy in patients with NDs or clinical syndromes that lead to cognitive decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Scopus, Web of Science, and Cochrane databases, since inception till 20th August 2024, identified randomized controlled trials (RCTs) and comparative studies that measured hippocampal volume changes in elderly patients with NDs and other clinical syndromes. Random effect model was employed to estimate the pooled atrophy rates. Subgroup analysis was conducted by disease, dosage, and side of the measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 5,943 initially screened studies, nine were included in the review, and six were analyzed in the meta-analysis, encompassing a total of 2,179 participants. The meta-analysis showed that donepezil at a 10\u00a0mg dose significantly reduced hippocampal atrophy compared to placebo (SMD\u2009=\u20090.44, 95% CI [0.08 to 0.81],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), whereas the 5\u00a0mg dose showed no significant effect on hippocampal volume. Overall, pooled results favored donepezil in reducing hippocampal atrophy (SMD\u2009=\u20090.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), indicating that higher doses are more effective. Among patients with mild cognitive impairment (MCI), both donepezil and vitamin E were associated with a significant reduction in hippocampal atrophy compared to placebo (SMD\u2009=\u20090.27,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). In contrast, galantamine did not significantly reduce hippocampal atrophy in the overall analysis, but it was associated with reduced whole brain atrophy in APOE \u03b54 carriers. Further analysis revealed no significant difference in the reduction of right or left hippocampal atrophy in donepezil-treated patients. These findings suggest that donepezil, particularly at higher doses, may have a protective effect against hippocampal atrophy in patients with AD and MCI, while galantamine\u2019s effect may be more limited, especially in certain genetic subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher doses of donepezil (10\u00a0mg) significantly reduce hippocampal atrophy in Alzheimer\u2019s disease and mild cognitive impairment, suggesting potential neuroprotective effects. In contrast, lower doses (5\u00a0mg) and galantamine showed no significant impact on hippocampal volume, though galantamine reduced whole brain atrophy in APOE \u03b54 carriers. Dosage and genetic factors are crucial in determining the efficacy of acetylcholinesterase inhibitors in slowing neurodegeneration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-024-03933-4","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T04:23:21Z","timestamp":1739334201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Youssef A.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Haitham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Walid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazim","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef M. Abd","family":"El-Satar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"3933_CR1","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.3390\/ijms10062510","volume":"10","author":"YE Choonara","year":"2009","unstructured":"Choonara YE, Pillay V, Du Toit LC, Modi G, Naidoo D, Ndesendo VM, Sibambo SR. Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. Int J Mol Sci. 2009;10:2510\u201357. https:\/\/doi.org\/10.3390\/ijms10062510.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3933_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the Common Neurodegenerative disorders: current therapeutic approaches and the potential role of Nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. https:\/\/doi.org\/10.3390\/ijms23031851.","journal-title":"Int J Mol Sci"},{"key":"3933_CR3","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1056\/NEJM199906243402507","volume":"340","author":"JB Martin","year":"1999","unstructured":"Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med. 1999;340:1970\u201380. https:\/\/doi.org\/10.1056\/NEJM199906243402507.","journal-title":"N Engl J Med"},{"key":"3933_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","volume":"19","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, Deuschl G, Parmar P, Brainin M, Murray C. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2019;19:255\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(19)30411-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"3933_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499\u2013502. https:\/\/doi.org\/10.1242\/dmm.030205.","journal-title":"Dis Model Mech"},{"issue":"3","key":"3933_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"MB Colovi\u0107","year":"2013","unstructured":"Colovi\u0107 MB, Krsti\u0107 DZ, Lazarevi\u0107-Pa\u0161ti TD, Bond\u017ei\u0107 AM, Vasi\u0107 VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315\u201335. https:\/\/doi.org\/10.2174\/1570159X11311030006.","journal-title":"Curr Neuropharmacol"},{"issue":"17","key":"3933_CR7","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.3390\/ijms22179290","volume":"22","author":"\u0141J Walczak-Nowicka","year":"2021","unstructured":"Walczak-Nowicka \u0141J, Herbet M. Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their Pathogenesis. Int J Mol Sci. 2021;22(17):9290. https:\/\/doi.org\/10.3390\/ijms22179290.","journal-title":"Int J Mol Sci"},{"key":"3933_CR8","unstructured":"Kumar A, Gupta V, Sharma S. Donepezil. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 17, 2023."},{"key":"3933_CR9","first-page":"19","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J, Lee HJ, Park SK, Park JH, Jeong HR, Lee S, Lee H, Seol E, Hoe HS. Donepezil regulates LPS and A\u03b2-Stimulated neuroinflammation through MAPK\/NLRP3 Inflammasome\/STAT3 signaling. Int J Mol Sci. 2021;22:19.","journal-title":"Int J Mol Sci"},{"key":"3933_CR10","doi-asserted-by":"publisher","unstructured":"Birks JS, Grimley Evans J. Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2015;4CD001191. https:\/\/doi.org\/10.1002\/14651858.CD001191.pub3.","DOI":"10.1002\/14651858.CD001191.pub3"},{"issue":"2","key":"3933_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3892\/etm.2020.8872","volume":"20","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yu R, Wang H, Zheng R. Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer\u2019s disease. Exp Ther Med. 2020;20(2):1789\u201395. https:\/\/doi.org\/10.3892\/etm.2020.8872.","journal-title":"Exp Ther Med"},{"key":"3933_CR12","first-page":"1","volume":"5","author":"B Seltzer","year":"2010","unstructured":"Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer\u2019s disease. Clin Interv Aging. 2010;5:1\u20136.","journal-title":"Clin Interv Aging"},{"key":"3933_CR13","doi-asserted-by":"publisher","first-page":"e6887","DOI":"10.7717\/peerj.6887","volume":"7","author":"YT Lin","year":"2019","unstructured":"Lin YT, Chou MC, Wu SJ, Yang YH. Galantamine plasma concentration and cognitive response in Alzheimer\u2019s disease. PeerJ. 2019;7:e6887. https:\/\/doi.org\/10.7717\/peerj.6887.","journal-title":"PeerJ"},{"issue":"4","key":"3933_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/0972-2327.104323","volume":"15","author":"KS Anand","year":"2012","unstructured":"Anand KS, Dhikav V. Hippocampus in health and disease: an overview. Ann Indian Acad Neurol. 2012;15(4):239\u201346. https:\/\/doi.org\/10.4103\/0972-2327.104323.","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"3933_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1042\/BST0380977","volume":"38","author":"J Avila","year":"2010","unstructured":"Avila J, G\u00f3mez de Barreda E, Engel T, Lucas JJ, Hern\u00e1ndez F. Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochem Soc Trans. 2010;38(4):977\u201380. https:\/\/doi.org\/10.1042\/BST0380977.","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"3933_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/hbm.20934","volume":"31","author":"SG Mueller","year":"2010","unstructured":"Mueller SG, Schuff N, Yaffe K, Madison C, Miller B, Weiner MW. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer\u2019s disease. Hum Brain Mapp. 2010;31(9):1339\u201347. https:\/\/doi.org\/10.1002\/hbm.20934.","journal-title":"Hum Brain Mapp"},{"issue":"2","key":"3933_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","volume":"6","author":"GB Frisoni","year":"2010","unstructured":"Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67\u201377. https:\/\/doi.org\/10.1038\/nrneurol.2009.215.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3933_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11586390-000000000-00000","volume":"28","author":"V Dhikav","year":"2011","unstructured":"Dhikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer\u2019s disease. Drugs Aging. 2011;28(1):1\u201311. https:\/\/doi.org\/10.2165\/11586390-000000000-00000.","journal-title":"Drugs Aging"},{"key":"3933_CR19","doi-asserted-by":"crossref","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1). https:\/\/perspectivesinmedicine.cshlp.org\/content\/1\/1\/a006189","DOI":"10.1101\/cshperspect.a006189"},{"issue":"9","key":"3933_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","volume":"11","author":"B Dubois","year":"2015","unstructured":"Dubois B, Chupin M, Hampel H, et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(9):1041\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.003.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"3933_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.162.4.676","volume":"162","author":"M Hashimoto","year":"2005","unstructured":"Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer\u2019s disease? Am J Psychiatry. 2005;162(4):676\u201382. https:\/\/doi.org\/10.1176\/appi.ajp.162.4.676.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"3933_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.neurobiolaging.2007.03.004","volume":"29","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29(9):1285\u201395. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.03.004.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"3933_CR23","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","volume":"160","author":"KR Krishnan","year":"2003","unstructured":"Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer\u2019s disease. Am J Psychiatry. 2003;160(11):2003\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.160.11.2003.","journal-title":"Am J Psychiatry"},{"key":"3933_CR24","doi-asserted-by":"publisher","unstructured":"Prins ND, van der Flier WA, Knol DL et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimers Res Ther. 2014;6(4):47. https:\/\/doi.org\/10.1186\/alzrt275","DOI":"10.1186\/alzrt275"},{"issue":"6","key":"3933_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","volume":"41","author":"GC Rom\u00e1n","year":"2010","unstructured":"Rom\u00e1n GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41(6):1213\u201321. https:\/\/doi.org\/10.1161\/STROKEAHA.109.570077.","journal-title":"Stroke"},{"issue":"12","key":"3933_CR26","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.neurobiolaging.2010.04.005","volume":"32","author":"N Schuff","year":"2011","unstructured":"Schuff N, Suhy J, Goldman R, et al. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging. 2011;32(12):2318. 2.318E41. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.04.005.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3933_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/JAD-190623","volume":"76","author":"E Traini","year":"2020","unstructured":"Traini E, Carotenuto A, Fasanaro AM, Amenta F. Volume analysis of Brain cognitive areas in Alzheimer\u2019s Disease: interim 3-Year results from the ASCOMALVA Trial. J Alzheimers Dis. 2020;76(1):317\u201329. https:\/\/doi.org\/10.3233\/JAD-190623.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"3933_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.mri.2016.04.025","volume":"34","author":"CM Moon","year":"2016","unstructured":"Moon CM, Kim BC, Jeong GW. Effects of Donepezil on brain morphometric and metabolic changes in patients with Alzheimer\u2019s disease: a DARTEL-based VBM and (1)H-MRS. Magn Reson Imaging. 2016;34(7):1008\u201316. https:\/\/doi.org\/10.1016\/j.mri.2016.04.025.","journal-title":"Magn Reson Imaging"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03933-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:48:30Z","timestamp":1739443710000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03933-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3933"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03933-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4857422\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study formal consent is not required. This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to Participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}